Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor Positive, HER2 Negative Breast Cancer Patients

被引：0
作者：
Friedman-Eldar, O. [1 ]
Ozmen, T. [1 ]
Reyes, F. Valle [1 ]
Goel, N. [1 ]
Tjendra, Y. [1 ]
Moller, M. [1 ]
Kesmodel, S. B. [1 ]
Franceschi, D. [1 ]
Avisar, E. [1 ]
机构：
[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2021年 / 28卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P59
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [1] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast Cancer
    Friedman-Eldar, Orli
    Ozmen, Tolga
    Reyes, Fernando Valle
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susane B.
    Moller, Mecker
    Franceschi, Dido
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236
  • [2] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes
    Orli Friedman-Eldar
    Tolga Ozmen
    Salah James El Haddi
    Neha Goel
    Youley Tjendra
    Susan B. Kesmodel
    Mecker G. Moller
    Dido Franceschi
    Christina Layton
    Eli Avisar
    Annals of Surgical Oncology, 2022, 29 : 4092 - 4101
  • [3] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes
    Friedman-Eldar, Orli
    Ozmen, Tolga
    El Haddi, Salah James
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susan B.
    Moller, Mecker G.
    Franceschi, Dido
    Layton, Christina
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (07) : 4092 - 4101
  • [4] HER2 and response to paclitaxel in node-positive breast cancer
    Nash, Irwin
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02) : 198 - 198
  • [5] Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
    Mou, Exian
    Ji, Juan
    Liu, Shiwei
    Shu, Lan
    Zou, Liqun
    Li, Zhuoxuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [6] Pathologic response to neoadjuvant therapy in HER2 positive/oestrogen receptor positive breast cancer patients
    Gasol Cudos, A.
    Morales, S.
    Rodriguez Galindo, A.
    Velasco Sanchez, A.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S333 - S333
  • [7] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    LABORATORY INVESTIGATION, 2012, 92 : 26A - 26A
  • [8] HER2 and response to paclitaxel in node-positive breast cancer
    Hayes, Daniel F.
    Thor, Ann D.
    Dressler, Lynn G.
    Weaver, Donald
    Edgerton, Susan
    Cowan, David
    Broadwater, Gloria
    Goldstein, Lori J.
    Martino, Silvana
    Ingle, James N.
    Henderson, I. Craig
    Norton, Larry
    Winer, Eric P.
    Hudis, Clifford A.
    Ellis, Matthew J.
    Berry, Donald A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) : 1496 - 1506
  • [9] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    MODERN PATHOLOGY, 2012, 25 : 26A - 26A
  • [10] Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer
    Cha, Chihwan
    Ahn, Sung Gwe
    Kim, Dooreh
    Lee, Janghee
    Park, Soeun
    Bae, Soong June
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Kim, Seung Il
    Park, Byeong-Woo
    Jeong, Joon
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (08) : 1585 - 1592
12345